CAPITAL THESIS

Independent equity research · SPRB · full edition

Spruce BiosciencesFrom a promising biomarker to a funded, reimbursed treatment — and a return per share.

A source-checked assessment of TA-ERT evidence, the planned accelerated-approval route, cash runway, debt and licence claims, future dilution and conditional five-year outcomes.

Research date: 29 October 2026 · USD common equity · Reference price: USD 46.99 · Observation: 2026-10-28

Speculative watchlist · regulatory and financing proof required

The investment decision

The successful-launch base returns 4.5% annually from $46.99, with a conditional 20% entry of $23.58. Failure can mean a total loss. Approval alone is insufficient: patient access, pricing and dilution determine the shareholder outcome.

June unrestricted cash$96.3mReported balance; not October cash
H1 operating cash used$30.9mNo product revenue
Base 2031 paying equivalents300Conditional approval/access assumption
Base five-year return+4.5% p.a.After funded dilution and licence reserve

Edition update. 29 October Sydney initiation. Reference: 28 October US regular close. Latest financials 30 June; August financing andOctober clinical context separately dated. No verified approval or filing acceptance.

01. A credible treatment hypothesis still needs an investable funding path

Research view: speculative watchlist; wait for regulatory and financing evidence. At $46.99, our successful-launch base produces only 4.5% a year over five years after funding and dilution. Its conditional 20% hurdle is $23.58. A more successful global launch produces a much larger outcome, while a failed programme can leave common shareholders with nothing. The base is not the expected outcome and its entry price is not risk-adjusted fair value.

Spruce is pursuing an enzyme replacement therapy for Sanfilippo syndrome type B, a devastating rare childhood disorder. The biological rationale and biomarker response warrant attention. The investment question is narrower: can the company secure approval, establish reimbursed treatment and fund a durable franchise without issuing so many shares that clinical success fails to reward existing owners? [S1] [S3]

The market already values the business above a stale net-cash calculation. A large percentage change in a small patient population can transform sales; the same small population makes diagnosis, trial recruitment, delivery capacity and individual treatment persistence decisive. We do not infer mispricing from the old share-price peak, orphan designation or the possibility of a priority review voucher.

The variant debate is therefore not simply whether the drug works. It is how strong the evidence must become, how soon cash receipts begin, and what is left per share after royalties, milestones, debt and future equity raises. Our cautious base does not clear a high return hurdle at the reference price even before assigning a probability to clinical or regulatory failure.

02. What is current, and what remains a plan

Spruce Biosciences, Inc. is Nasdaq: SPRB, CIK 1683553; it is not the separately listed Spruce Power. Research date: 29 October 2026, Australia/Sydney. Reference price USD 46.99 on 2026-10-28. This is the completed 28 October US regular-session close, corroborated by SIP market data and ChartExchange. It is not an after-hours quote. The financial balance sheet is dated 30 June, and the common-share bridge includes the August placement. [S1] [S9]

Latest regulatory position reviewed: the 24 August company announcement still planned a Q4 2026 BLA submission. No verified submission, acceptance, approval or FDA decision deadline was found in the later releases reviewed through 29 October. The newer registries list TrAnsform as not yet recruiting and expanded access as available; neither proves commercial approval. October natural-history research is useful context, not a new randomized treatment result. September-quarter financials were not available in this research set. [S2] [S5] [S10] [S13] [S14]

All dollars are USD. Model financials are in millions; share counts are in millions unless written in full. All historical per-share and share data use the August 2025 one-for-75 reverse-split basis. Operating forecasts, treatment prices, success sensitivities and exit multiples are Capital Thesis assumptions. No broker target or refreshed consensus is presented as a fact. [S1]

Evidence confidence is high for filed financials and the dated company disclosures, but lower for commercial uptake and regulatory outcomes. Underwriting remains conditional. No current positive earnings multiple exists, so the report deliberately omits a cross-company return ranking and an invented no-rerating comparison.

03. The treatment mechanism — and why delivery is part of the economics

MPS IIIB results from deficient NAGLU enzyme activity. Heparan sulfate accumulates in cellular recycling compartments and the nervous system progressively deteriorates. TA-ERT, tralesinidase alfa, combines replacement enzyme with a targeting component intended to improve cellular uptake. It is investigational; the aim is to reduce substrate accumulation and preserve function, not to claim a proven cure. [S3] [S4]

The therapy does not cross the blood-brain barrier adequately through ordinary systemic administration. It is delivered into cerebrospinal fluid through an implanted intracerebroventricular reservoir and catheter. The proposed expanded-access regimen is weekly. This creates recurring treatment revenue only if approval, reimbursement, functioning delivery centres and sustained patient access all materialise. [S3] [S4] [S11]

Weekly administration also creates a burden that a simple population-times-price calculation misses: surgery and device management, travel, specialist staff, infection surveillance and treatment interruptions. A price or reimbursement decision that covers the drug does not automatically eliminate these access constraints. Earlier diagnosis may improve the potential treatment opportunity, but it is not equivalent to a diagnosed, eligible and reimbursed patient today.

TA-ERT rights were acquired from the Allievex creditor-assignment process in 2024 together with the BioMarin licence. Spruce also holds the earlier-stage SPR202 programme. We assign zero value to that programme, tildacerfont and acquisition premiums in the model. This is a conservative single-asset analysis, not a claim that those assets have no scientific value. [S1] [S3]

04. What the clinical evidence supports — and does not prove

EvidenceWhat it establishesWhat it cannot establish alone
Published 22-patient Phase 1/2 studyBiochemical response and an observed safety/clinical data set after ICV treatment.A randomized estimate of long-term clinical benefit.
Long-term extensions and natural-history comparisonsDurability information and a comparator for the disease course.Complete protection against selection, survivor and measurement biases.
October 2026 natural-history posterDisease progression in an untreated cohort; 40 severe cases analysed from 44 enrolled.Treatment efficacy: no investigational treatment comparison was conducted in that study.
Planned TrAnsform confirmatory studyA proposed controlled test of cognition in young children.Results, until patients are enrolled, followed and analysed.

The peer-reviewed study reported marked reductions in CSF heparan-sulfate biomarkers and observed associations with brain-volume and cognitive measures. It was open-label, with 22 treated participants. Small sample size and natural-history comparisons mean the data should not be described as randomized proof of preserved cognition. Investigators reported drug-related and device-related serious adverse events, including inflammatory symptoms, infection and device complications. [S4]

Spruce reports encouraging longer-term cognition and adaptive-function comparisons with untreated cohorts. These strengthen the rationale for further assessment but do not remove the distinction between a surrogate biomarker and a patient benefit. An approval route can accept a surrogate reasonably likely to predict benefit while still requiring confirmation afterward. [S2] [S3]

The October poster is specifically a noninterventional natural-history analysis. Its longitudinal data largely came from ages five to eleven, limiting extrapolation outside that range. The study can inform diagnosis and future endpoint interpretation; presenting it as a fresh successful drug trial would materially overstate the news. [S5]

05. Filing, review and approval are separate milestones

Spruce seeks accelerated approval based on CSF HS-NRE reduction. In August it said FDA found its manufacturing comparability strategies reasonable and aligned on the planned application format. Manufacturing transfer and a first process-performance qualification batch had progressed. The company planned a first PPQ batch in the application and a second batch before mid-cycle review. This is encouraging preparation, not an FDA approval decision. [S2]

The company also said FDA indicated that its integrated completed studies and natural-history data could potentially support review of the biomarker effect as an adequate and well-controlled study. A randomized pre-approval efficacy trial is therefore not asserted here as a universal legal requirement. The remaining question is whether the full application satisfies the agency and whether subsequent clinical confirmation succeeds. [S2]

StageDated status / requirementInvestment interpretation
BLA submissionPlanned for Q4 2026 in the August update.An announced filing would reduce a timing uncertainty; it would not establish approvability.
Manufacturing and safety reviewCommercial-scale process comparability, PPQ data and safety remain relevant.A delay can extend cash burn even without a change in biological efficacy.
Confirmatory study14 estimated children aged 1–5; registry not yet recruiting, estimated start December 2026.Clinical benefit still needs to be demonstrated; recruitment is difficult in an ultra-rare disorder.
Expanded accessRegistry available from its 6 October update; approximately 10 US participants planned.Availability is not proof of dosing, commercial revenue or approval.
Potential launchCompany discussed potential US launch in 2027; the model assumes conditional timing.Requires a usable label, supply, treatment sites, reimbursement and funding.

The TrAnsform registry, last updated 21 September, estimates a December 2026 start and August 2033 primary completion, with the cognitive endpoint measured at week 260. The EAP registry was updated 6 October to available and lists a US site. Registry status and company plans do not prove that the first participant has been treated. We do not attach an invented PDUFA date. [S13] [S14]

Confirmatory follow-up may therefore extend beyond the model’s 2031 exit. The terminal multiple assumes an ongoing funded franchise despite unresolved confirmation risk, not an already completed five-year controlled result. A manufacturing request, refusal to file, clinical hold, restrictive label or need for more efficacy data can materially change both the timeline and funding requirement.

Orphan, fast-track and breakthrough designations provide a regulatory framework, not a guarantee. A potential priority review voucher is excluded entirely from valuation and cash runway: its award, eligibility and sale proceeds are uncertain. A rival gene therapy or a less burdensome delivery method could also alter long-term demand.

06. A small population is not the same as a small opportunity — or easy access

The August corporate deck estimates more than 3,000 patients across selected commercial territories, including roughly 450 in North America and 500 in its Europe/Middle East grouping. These are company estimates derived from incidence and lifespan assumptions, not a count of diagnosed, treatment-ready customers. Geographic categories include countries with different approval, reimbursement and delivery systems. [S6]

Our base assumes 300 annual paying treatment equivalents in 2031: 180 in North America and 120 in selected European markets. The first US commercial receipts are assumed in the second half of 2027; later Canadian and European access requires separate permissions. At $750,000 net revenue per North American treatment-year and $375,000 in Europe, annual revenue is $180m. The resulting $600,000 blended net price is a house assumption, not a launch-price announcement.

A treatment equivalent represents a full year of paid therapy; two patients treated for half a year equal one equivalent. This incorporates partial-year starts and interruptions in the count rather than assuming every enrollee produces a full year of revenue. The model requires no access to the full global prevalence estimate. Even 180 North American equivalents would be substantial penetration of the deck’s estimated population.

The company cites high annual costs for other ultra-rare therapies. Those precedents support considering premium pricing but do not establish TA-ERT’s net price, discounts, public-payer coverage or commercial label. Lower price, delayed diagnosis, narrow eligibility, caregiver burden and treatment discontinuation can all reduce realised revenue. [S6]

The bull is more ambitious: 550 equivalents by 2031, including 100 in selected Asia-Pacific markets, with $320m of net sales. It assumes broader approvals, stronger uptake and a more favourable price mix. That is an upside commercial outcome, not a probability-weighted forecast or the number of patients already on treatment.

07. Cash rose because financing outweighed a growing cash burn

Reported metric, $mH1 2025H1 2026
Revenue0.0000.000
R&D expense10.40719.738
G&A expense6.7778.761
Net loss16.10828.495
Operating cash used21.55530.852
Cash PP&E purchases0.0000.145
Stock compensation0.4671.560

Manufacturing scale-up and clinical development explain much of the higher spending; pre-launch staffing and professional costs also rise before revenue. R&D expense in the prior-year June quarter included unusual reversals, making a single-quarter percentage comparison particularly unhelpful. First-half expenses give a clearer scale, while the actual cash-flow statement governs runway. [S1] [S11]

First-half loss was $28.495m but operating cash use was $30.852m. Stock compensation and noncash charges partly offset the loss, while prepayments, other assets and accrued-liability settlements consumed cash. The $2.6m Allievex receivable collected in January was a non-recurring benefit within the cash conversion picture; repeating a simple historical burn rate would not be a prudent launch forecast. [S1]

The cash-flow bridge is exact: cash plus restricted cash started at $48.942m, operating activities used $30.852m, investing used $0.145m and financing provided $78.386m, leaving $96.331m. Of that, $0.036m was restricted. April’s public offering raised $69m gross and approximately $64.4m net. Foundation investment in August provided another $5.5m gross for new shares. Neither is product revenue. [S1] [S7]

Management said June cash could fund planned operations and debt obligations into the second half of 2027. That is a dated management assessment, not a promise to reach profitability or a statement of October bank cash. Our opening-2027 estimate deducts $35m of H2 operating cash costs, $0.5m capex and $0.939m debt service from June cash plus the August gross proceeds, leaving $65.356m. These H2 uses are explicit assumptions.

08. Debt, licences and dilution are real claims on a future launch

Capital itemFiled / derived amountModel treatment
Common stock1,372,043 Dec 2025; 2,752,810 June 2026; 2,874,013 pro forma August.The April pre-funded warrants were exercised and are already included.
Awards49,174 options and 127,084 RSUs at June.All counted as full opening shares without option cash credit; future awards add 3% annually.
Legacy warrants169,147 at $297.02.Not assumed exercised before their 2028 expiry; separate dilution stress.
Avenue warrant64,000 at $50; expires 31 January 2031.Full shares reserved with no exercise-cash benefit, conservatively.
Loan conversionLender option to convert up to $4m at $60.No conversion assumed; all principal repaid in cash.
Loan obligation$15m principal plus $1.6m final fee, versus $7.091m carrying value.Filed cash-service schedule used; zero terminal debt.
BioMarin licenceUp to $25.5m development/regulatory and $100m sales milestones; tiered royalties.10% royalty; explicit payment/reserve schedule below.

The fully counted instrument ceiling is about 3.350m shares before future awards or raises, including every warrant, option, RSU and the $4m conversion option. It is not GAAP diluted EPS or a forecast of simultaneous exercise. Loss-period diluted EPS excludes anti-dilutive instruments; using its weighted-average denominator for valuation would miss future claims. [S1] [S6] [S7]

The Avenue facility headline is up to $50m, but only $15m was funded at June. The $10m second-tranche availability window ended on 30 September absent an amendment or completed draw not verified here. Another $15m tranche and a discretionary $10m tranche remain subject to milestones and other conditions. We count none of this unconfirmed capacity as cash. [S1] [S8]

The loan’s stated June rate was 12.25%, with a 12.25% floor and prime-linked formula. Absent milestone extensions, principal amortisation begins after the initial interest-only period in January 2027 and final maturity is July 2029. The model uses $7.020m, $6.778m and $5.207m of combined debt service in 2027–2029, including the final fee. Assets and intellectual property secure the loan, so existing cash is not an equity liquidation floor. [S1] [S8]

Licence economics are also not optional. The base assumes all $25.5m development/regulatory milestones paid in 2027, $25m of sales milestones paid in 2029–2031 and a $75m reserve deducted from terminal equity. The bull pays the full $100m sales maximum before exit. Exact sales thresholds are not public in the evidence reviewed: these allocations are conservative assumptions, not a claim that every milestone is currently due. [S1] [S3]

The licence reserve can overstate eventual payments if thresholds are never reached, and its undiscounted terminal treatment is cautious. Conversely, faster-triggering obligations would increase early funding needs. HBM obligations of up to $390m relate to SPR202, an excluded programme; they are not silently charged to TA-ERT. Additional development or acquisitions would require a separate budget and valuation. [S1]

09. A funded five-year launch path, not a revenue multiple shortcut

Base assumption / output20272028202920302031
Annual paying equivalents2580160240300
Net sales, $m18.7552.50101.25146.25180.00
Cash fixed costs, $m60.065.070.075.080.0
EBIT, $m-49.81-32.88-6.1918.0635.00
Gross new equity, $m42.3347.5725.223.410.00
Assumed issue price, $4050606570
Ending cash, $m20.0020.0020.0020.0031.19
Shares before warrant reserve, m4.2325.3395.9326.1646.349

The base charges 25% of revenue for production/supply and 10% royalties, then $60m rising to $80m of cash R&D and commercial/administrative costs. Capex and depreciation are $2m a year. Working capital is 15% of revenue; increasing sales therefore consumes cash before it fully supports funding. Cash tax is 25% of positive EBIT, without assigning value to loss carryforwards or interest tax shields.

When projected cash falls below $20m, the model raises equity at the stated fixed issue prices, paying 6% fees. It requires $118.53m gross over the five years. Existing awards are counted from the start; an additional 3% of shares is issued each year after financing to compensate employees. Cash costs exclude stock compensation, so the award dilution is not deducted a second time as cash expense. The model finishes with 6.413m shares including the Avenue warrant reserve.

The fundraising path is a critical assumption. A company cannot guarantee issuance at $40, $50 or $60 when it needs capital; a disappointing regulatory event may make any raise impossible. The bull needs less funding despite higher commercial growth because it generates cash sooner and sells new shares at higher assumed prices. This is why identical asset success need not produce identical returns for existing investors.

The model reserves Avenue shares without exercise proceeds even though exercise would require timing and a suitable price before expiry. Legacy warrants are excluded from the main scenarios rather than assumed to convert at a 2031 price after expiry. As a conservative additional share-only stress, adding all 169,147 legacy warrant shares without any cash proceeds lowers the base terminal value to about $57.16; actual exercise could also provide cash. Loan conversion is a separate alternative, not added on top of cash repayment.

No dividend, buyback, voucher sale, other pipeline asset or takeover premium supports the return. The terminal value uses FY2031 operations as a five-year proxy from the October 2026 reference; it is not an exact-date liquidation forecast. Nominal USD returns exclude investor taxes, transaction costs and foreign exchange.

10. The upside is real in the model — and so is a complete loss

Conditional caseFailure / bearApproved-launch baseFaster global bull
2031 paying equivalents0300550
Revenue, $m0180.0320.0
EBIT, $mNot applicable35.0114.6
Exit EV / EBITNo franchise value12x14x
Terminal cash, $m031.1996.63
Remaining milestone reserve, $mNot applicable75.00.0
Terminal shares, mResidual claim only6.4135.222
Terminal value per share$0.00$58.66$325.73
Five-year annualised returnTotal loss+4.5%+47.3%

The bear assumes approval fails and a wind-down follows. Starting from the same $65.356m opening-2027 cash, $45m of 2027 operating costs, capex, $15m wind-down costs and the remaining debt service exhaust the residual claim. Common value is zero. This represents 100% total capital loss; the mathematical CAGR of a zero terminal value is −100%. It is a severe scenario, not a forecast that investors lose 100% in each year or the only way the thesis can fail.

The base calculation is ($35m × 12 + $31.1875m cash − $75m licence reserve) / 6.412597m shares = $58.66. The bull uses $114.6m EBIT × 14, plus $96.63m retained cash and 5.222231m shares. All debt has been serviced and paid. The different multiples reflect different assumed durability and growth, not a measured market consensus.

The base is conditional on approval and a sustained funded launch. A restrictive label, slower launch or commercial failure after approval can produce losses between the illustrated outcomes. The bull is sensitive to international access, net price and scale economics. Averaging the three case CAGRs would be mathematically inappropriate and would hide the binary risk.

11. A low conditional entry is not a safe price

A conditional 20% annual base-case return over five years requires an entry price of $23.58, holding the successful launch, financing, dilution, licence reserve and 12x exit multiple fixed. This is terminal value divided by 1.20^5. It is not a claim that approval is likely, that this price will be available or that buying there ensures a return.

Future issue-price sensitivityGross raised, $mTerminal shares, mBase CAGR20% conditional entry
-25% versus base118.537.350+1.7%$20.57
+0% versus base118.536.413+4.5%$23.58
+25% versus base118.535.850+6.5%$25.84

This financing sensitivity recalculates the entire share path and subsequent award dilution. Gross funding needs remain unchanged because operating cash needs do not depend on the investor’s entry price. Lower future issuance prices transfer more of the eventual franchise to new capital. These sensitivities are more useful than treating today’s share count as fixed.

2031 paying equivalents8x exit: 20% entry12x exit: 20% entry16x exit: 20% entry
200$0.00$0.00$0.00
300$14.80$23.58$32.35
400$34.35$52.91$71.46

The patient/multiple grid changes terminal operating value only, holding interim cash, funding and dilution fixed. It is not a fully financed alternative operating case. A lower uptake path throughout the period would normally require additional capital and could be worse than the table. A slow launch can also trigger insolvency before any terminal value is reached.

Milestone timing matters. Paying all $100m sales milestones early increases base gross funding to $186.41m and gives a $57.39 terminal price. The optimistic alternative with no sales-milestone charge or reserve gives $74.76. Neither is a disclosed contractual payment schedule.

Illustrative success probabilityDiscounted terminal payoff at 15%20% expected-payoff hurdle
25%$15.59$12.60
50%$31.18$25.20
75%$46.77$37.81
100%$62.36$50.41

This probability table assumes, purely for sensitivity, that successful outcomes are 75% base and 25% bull, while failure pays zero. Under that mix, a 75.4% success probability is required for the expected terminal payoff discounted at 15% to equal $46.99. No such probability is endorsed. Altering the success mix changes the answer substantially; clinical success, funded launch and commercial uptake are not one interchangeable event.

The probability calculation discounts terminal per-share payoffs after all scenario funding and dilution; it is not a clinical-trial success estimate or a full perpetual-growth DCF. A simple base-only success path, even at 100% probability, does not support a 15% hurdle at $46.99. The present price needs more optimistic outcomes, a lower required return or less costly financing/licence economics than the base.

12. What would strengthen or kill the thesis

Evidence windowUpgrade evidenceRe-underwrite / failure evidence
Q4 2026 planned milestonesA documented BLA submission; accepted review and confirmatory first-patient dosing subsequently confirmed.Filing delay, new manufacturing requirements, trial-start problems or a regulatory hold.
Next financial filingUpdated cash, burn, actual debt draws and share issuance reconcile to a credible launch runway.Higher spending, unavailable funding or materially discounted issuance.
Regulatory reviewManufacturing quality, clinical/safety package and a commercially usable label.Rejection, restrictive label or a requirement for additional long-duration evidence.
Conditional 2027–2029 launchTreatment-centre readiness, reimbursement, patient starts and persistence.Low diagnosis/access, poor net price, interruptions or high device burden.
Confirmatory follow-upCognitive benefit and acceptable safety with an interpretable controlled comparison.Failure to confirm benefit, unacceptable adverse events or withdrawal risk.

Other risks include dependence on third-party manufacturing, a single principal asset, IP and licence continuity, competition from newer delivery approaches, leadership execution and a thinly traded share base. A single small study cannot eliminate unknown safety risks. A 10-Q estimate of cash runway cannot guarantee access to capital after a negative event. [S1] [S3]

Short interest, an executable borrowing quote and a refreshed institutional-ownership/float analysis were not independently obtained for this edition. No squeeze thesis or short recommendation is inferred. The reported common-share count is dated, not a real-time register; subsequent ATM issuance, awards or exercises may alter it. These gaps reinforce a watchlist posture rather than justify invented precision.

The research set contains no verified current launch price, regulatory approval probability, complete milestone threshold schedule or October cash statement. Those are the principal open inputs. The next useful evidence is a dated regulatory update and the next financial filing, not another calculation built on the same optimistic commercial assumptions.

Financial exhibits

Exact observations accompany every chart. Actuals, management guidance and Capital Thesis assumptions are labelled separately; the chart shapes do not imply probabilities.

Chart 01 · USD million

Cash burn increased before a potential launch

Clinical and manufacturing work consumes funding before commercial revenue exists.

R&D expenseG&A expenseOperating cash used
Cash burn increased before a potential launch (USD million). Exact figures in the table below.010203040H1 2025R&D expense: 10.407 USD million10.407G&A expense: 6.777 USD million6.777Operating cash used: 21.555 USD million21.555H1 2026R&D expense: 19.738 USD million19.738G&A expense: 8.761 USD million8.761Operating cash used: 30.852 USD million30.852
Exact values · USD million
ObservationR&D expenseG&A expenseOperating cash used
H1 202510.4076.77721.555
H1 202619.7388.76130.852

Reported six-month periods. Expense series and operating cash use overlap; do not add them together. Sources: [S1]

Chart 02 · USD million

Financing, not product sales, explains the cash increase

New equity and debt more than covered operating cash use in the first half.

Reported cash bridge components
Financing, not product sales, explains the cash increase (USD million). Exact figures in the table below.-50-250255075100Opening cash + restrictedReported cash bridge components: 48.942 USD million48.942Operating cash flowReported cash bridge components: -30.852 USD million-30.852Investing cash flowReported cash bridge components: -0.145 USD million-0.145Financing cash flowReported cash bridge components: 78.386 USD million78.386Closing cash + restrictedReported cash bridge components: 96.331 USD million96.331
Exact values · USD million
ObservationReported cash bridge components
Opening cash + restricted48.942
Operating cash flow-30.852
Investing cash flow-0.145
Financing cash flow78.386
Closing cash + restricted96.331

First half 2026. Endpoints are balances; middle observations are flows. June unrestricted cash is 96.295; restricted cash 0.036. Sources: [S1]

Chart 03 · Million common shares

The common-share base more than doubled

April and August funding reduced each existing share’s percentage ownership.

Common shares
The common-share base more than doubled (Million common shares). Exact figures in the table below.00.511.522.5331 Dec 2025Common shares: 1.372 Million common shares1.37230 Jun 2026Common shares: 2.7528 Million common shares2.7528Pro forma August 2026Common shares: 2.874 Million common shares2.874
Exact values · Million common shares
ObservationCommon shares
31 Dec 20251.372
30 Jun 20262.7528
Pro forma August 20262.874

Reported December/June counts plus 121,203 August placement shares. Excludes unvested awards, warrants and future raises; all counts split-adjusted. Sources: [S1] [S7]

Chart 04 · USD million

The base raises cash before it becomes self-funding

Even the approved-launch case requires substantial new equity.

Assumed net revenueGross equity raise
The base raises cash before it becomes self-funding (USD million). Exact figures in the table below.0501001502002027Assumed net revenue: 18.75 USD million18.75Gross equity raise: 42.3287 USD million42.32872028Assumed net revenue: 52.5 USD million52.5Gross equity raise: 47.5697 USD million47.56972029Assumed net revenue: 101.25 USD million101.25Gross equity raise: 25.2202 USD million25.22022030Assumed net revenue: 146.25 USD million146.25Gross equity raise: 3.4076 USD million3.40762031Assumed net revenue: 180 USD million180Gross equity raise: 0 USD million0
Exact values · USD million
ObservationAssumed net revenueGross equity raise
202718.7542.3287
202852.547.5697
2029101.2525.2202
2030146.253.4076
20311800

Capital Thesis conditional base. 25% production cost, 10% royalty, cash fixed cost 60–80m, milestone allocations, 6% equity fees and 20m cash floor. Not company guidance. Sources: [S1] [S6]

Chart 05 · Annual paying treatment equivalents

Patient access is the operating driver

The model assumes a staged regional launch, not conversion of the full prevalence estimate.

North America baseSelected Europe base
Patient access is the operating driver (Annual paying treatment equivalents). Exact figures in the table below.0501001502002027North America base: 25 Annual paying treatment equivalents25Selected Europe base: 0 Annual paying treatment equivalents02028North America base: 60 Annual paying treatment equivalents60Selected Europe base: 20 Annual paying treatment equivalents202029North America base: 110 Annual paying treatment equivalents110Selected Europe base: 50 Annual paying treatment equivalents502030North America base: 150 Annual paying treatment equivalents150Selected Europe base: 90 Annual paying treatment equivalents902031North America base: 180 Annual paying treatment equivalents180Selected Europe base: 120 Annual paying treatment equivalents120
Exact values · Annual paying treatment equivalents
ObservationNorth America baseSelected Europe base
2027250
20286020
202911050
203015090
2031180120

House assumptions after approval. Equivalent counts net partial-year treatment and interruptions. Separate regional approvals/reimbursement required. Sources: [S6]

Chart 06 · USD per share

Cheaper future issuance dilutes today’s owners more

The same cash requirement produces different per-share outcomes.

Conditional 20% entry
Cheaper future issuance dilutes today’s owners more (USD per share). Exact figures in the table below.051015202530Future raises −25%Conditional 20% entry: 20.5686 USD per share20.5686Base issue pricesConditional 20% entry: 23.5757 USD per share23.5757Future raises +25%Conditional 20% entry: 25.8425 USD per share25.8425
Exact values · USD per share
ObservationConditional 20% entry
Future raises −25%20.5686
Base issue prices23.5757
Future raises +25%25.8425

Full share-path recalculation, same operating cash path and 6% fees. These are future corporate issue prices, not variations in the investor entry price. Sources: [S1]

Chart 07 · USD per share

Conditional launch value has a very wide range

Failure can eliminate the entire common-equity claim.

Five-year terminal share value
Conditional launch value has a very wide range (USD per share). Exact figures in the table below.0100200300400Failure / bearFive-year terminal share value: 0 USD per share0Approved baseFive-year terminal share value: 58.6638 USD per share58.6638Faster global bullFive-year terminal share value: 325.7286 USD per share325.7286
Exact values · USD per share
ObservationFive-year terminal share value
Failure / bear0
Approved base58.6638
Faster global bull325.7286

Capital Thesis scenarios after debt, royalties, milestone reserves and dilution. No endorsed probabilities, no guaranteed return, no common dividends. Sources: [S1] [S6]

Source register and research basis

Evidence checked for this edition on 29 October 2026. Dates below identify source vintages. Company guidance and house scenarios are conditional; source links and the downloadable model allow the assumptions to be inspected.

S4 · Tralesinidase alfa Phase 1/2 clinical study

JCI 2023; article165076 · Primary peer-reviewed 22-patient open-label data. Biomarker response, exposure and reported drug/device safety; not randomized clinical proof.

https://www.jci.org/articles/view/165076
S13 · TrAnsform trial registry, NCT07579910

Last update posted 21 September 2026; accessed 29 October · Sponsor-maintained registry: not yet recruiting; estimated December 2026 start / August 2033 primary completion; 14 participants; cognition at week 260. Dates are estimates.

https://clinicaltrials.gov/study/NCT07579910
S14 · TA-ERT expanded-access registry, NCT07733856

Last update posted 6 October 2026; accessed 29 October · Sponsor-maintained registry: available, approximately 10 participants planned; weekly ICV delivery. Availability is not proof of dosing or approval.

https://clinicaltrials.gov/study/NCT07733856